Primary FDA-Approved Indications
Use is common for strongyloidiasis, onchocerciasis, and refractory scabies.
Strongyloidiasis
FDA ApprovedChildrenCDC guidance
Evidence Sources
()
Onchocerciasis
FDA ApprovedChildrenWHO guidance
Evidence Sources
()
Crusted scabies
FDA ApprovedChildren >=15 kgCDC guidance
Evidence Sources
()